With support from the University of Wisconsin-Milwaukee, the researchers found that jellyfish-based compound aequorin has yielded promising results. The scientists subjected brain cells to the “lab” equivalent of
Provenge is an investigational product that may represent the first in a new class of active cellular immunotherapies that are uniquely designed to stimulate a patient’s own immune
Results also demonstrated a low rate of side effects in treatment naive patients with genotype-1 HCV infection after 24 weeks of treatment. Earlier in the year the trial
The phase IIIb trial showed that the patch could offer individualized control over a child’s ADHD symptoms, allowing parents and physicians to better manage the potential for late-day
The study examined Vertex’s investigational hepatitis C virus protease inhibitor, telaprevir in combination with pegylated interferon (peg-IFN) with or without ribavirin. The hepatitis C virus was suppressed in
The work, which was directed by Dr Yun-Sil Lee from the Korea Institute of Radiological and Medical Sciences in Seoul, Korea, found that targeted overexpression of heat shock
Both a 750mg dose and 375mg dose of naproxcinod were evaluated in the study. Both were shown to be superior to placebo on all three efficacy endpoints of
The company reported third quarter 2006 net earnings from continuing operations of $338 million, compared to $964 million, for the same period in 2005. Bristol-Myers Squibb said the
In July 2003, Aspreva signed a collaboration agreement with Roche for the exclusive worldwide rights to develop and, upon regulatory approval, commercialize CellCept for all autoimmune disease applications.
The agreement includes an option for Merck to develop human monoclonal antibodies directed against antigens identified by Intercell to treat and protect against severe infections caused by group
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.